SalioGen Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- SalioGen Therapeutics's estimated annual revenue is currently $15.5M per year.
- SalioGen Therapeutics's estimated revenue per employee is $155,000
- SalioGen Therapeutics's total funding is $135M.
Employee Data
- SalioGen Therapeutics has 100 Employees.
- SalioGen Therapeutics grew their employee count by 37% last year.
SalioGen Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Head Finance | Reveal Email/Phone |
2 | VP, Portfolio and Program Management | Reveal Email/Phone |
3 | VP, Non-Clinical | Reveal Email/Phone |
4 | Associate Director Process Development | Reveal Email/Phone |
5 | Scientist II, Bioanalytical Development | Reveal Email/Phone |
6 | Associate Principal Scientist, Analytical Sciences | Reveal Email/Phone |
7 | Scientist II | Reveal Email/Phone |
8 | Scientist II, Platform Development & Genetic Engineering | Reveal Email/Phone |
9 | Research Associate | Reveal Email/Phone |
SalioGen Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 1 | -50% | N/A | N/A |
#3 | $5.1M | 33 | 22% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 2 | -60% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | N/A | 11 | 10% | N/A | N/A |
#10 | $5.4M | 29 | 0% | N/A | N/A |
What Is SalioGen Therapeutics?
SalioGen is advancing a new category of genetic medicine we call Gene Coding, which works by adding a new genomic code to turn on, off or modify the functions of new or existing genes. We are advancing potentially curative therapies, with an initial focus on developing durable, safe and accessible genetic medicine to more patients with inherited disorders. At SalioGen, we are driven not only by our efforts to realize the immense potential of our science, but also by our dedication and commitment to developing medicines that can make a significant impact on patients’ lives. Our Gene Coding approach is guided by our Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes we call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond. Looking ahead, SalioGen plans to explore Gene Coding’s capabilities to streamline cell therapy, cell engineering, and biologics manufacturing with the goal of helping an even broader population of patients in need.
keywords:N/A$135M
Total Funding
100
Number of Employees
$15.5M
Revenue (est)
37%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $395.2M | 100 | 9% | N/A |
#2 | $33.6M | 101 | 20% | N/A |
#3 | $36.6M | 102 | 17% | N/A |
#4 | $25.6M | 102 | 4% | $117.9M |
#5 | $28.4M | 103 | 30% | N/A |